What Medication Helps With Dissociation?

No medication is currently approved by the FDA specifically for treating dissociative disorders, and the research base remains thin compared with conditions like depression or anxiety. The drugs that show the most promise, including opioid antagonists like naltrexone and the antiepileptic lamotrigine, have only modest evidence behind them, mostly from small trials and open-label studies rather than the large randomized trials clinicians prefer. That does not mean medication is useless for dissociation, but it does mean prescribing involves a fair amount of educated guessing and off-label use, often targeting the conditions that travel alongside dissociation rather than dissociation itself.

Why There Is No Standard Drug Treatment

Dissociation is not a single symptom. It spans a wide range of experiences, from the detachment and unreality of depersonalization-derealization disorder to the identity disruptions seen in dissociative identity disorder, to the dissociative flashbacks and emotional numbing that accompany post-traumatic stress disorder. That diversity makes it hard to design a single drug trial that captures everyone who “dissociates.” A systematic review of pharmacotherapy for dissociative disorders found that paroxetine and naloxone were the only agents studied in randomized controlled trials and that the evidence for both was modest, with high variability across studies and very little literature overall.¹ A broader neurobiological review noted that no comprehensive pharmacological treatment exists for depersonalization-derealization disorder, in part because the brain circuits involved, spanning stress-response systems, emotional regulation networks, and body-awareness pathways, are complex and not fully mapped.²

The upshot is that most clinicians treat dissociation by targeting the symptoms that overlap with better-understood conditions: the depression, the anxiety, the PTSD flashbacks. The medications discussed below are all off-label for dissociation, and the quality of evidence ranges from “somewhat encouraging” to “barely studied.” That context matters, because a doctor suggesting naltrexone or lamotrigine for your dissociative symptoms is working from a playbook that is still being written.

Opioid Antagonists Are the Most Promising Lead

The most interesting pharmacological thread in dissociation research involves opioid antagonists, drugs that block opioid receptors in the brain. Naltrexone and its injectable cousin naloxone, both better known for treating addiction and overdose, have shown real potential for reducing dissociative symptoms. The underlying idea is that the brain’s own opioid system may play a role in producing the emotional numbing and detachment characteristic of dissociation. If dissociation is partly the brain dampening its own emotional circuits via endogenous opioids, then blocking those receptors could, in theory, let emotional experience flow more normally.

An open trial of naltrexone in patients with depersonalization disorder found an average 30% reduction in symptoms across three validated measures of dissociation. Three of the patients were classified as very much improved and one as much improved.³ That study was small and had no placebo group, but the results were striking for a condition that had resisted most prior treatments.

A 2023 systematic review that pooled data from multiple studies of opioid antagonists for dissociative symptoms found a large effect size in favor of treatment. The review cautioned that the included studies were quite varied in design and quality, and publication bias may have inflated the numbers. Still, the authors concluded that opioid antagonists, particularly naltrexone, are “promising candidates” for dissociative symptoms.⁴ This is the closest thing the field has to a well-supported pharmacological recommendation, and even it comes with significant caveats about the small number of studies and inconsistent methodology.

In practice, naltrexone is taken daily as a pill, typically at 50 mg, though some clinicians start lower and adjust. It is generally well tolerated but can cause nausea and headaches, and it is completely off the table for anyone taking opioid pain medications, because it would throw them into withdrawal. If you are being considered for naltrexone, your prescriber should verify you are not using any opioids before starting.

Antidepressants Alone Tend to Disappoint

Because depression and anxiety so frequently accompany dissociation, SSRIs like fluoxetine, sertraline, and paroxetine are often the first medications tried. For the depression and anxiety themselves, SSRIs can be genuinely helpful. For the dissociation specifically, the picture is less encouraging. A review of pharmacological approaches to depersonalization disorder characterized conventional antidepressants and antipsychotics as being “of little value” for the dissociative symptoms themselves.⁵

That said, paroxetine is one of the two agents with any randomized-trial backing for dissociation, according to the systematic review mentioned earlier.¹ It showed modest benefit for dissociative symptoms occurring alongside PTSD and borderline personality disorder. The effect was not dramatic, and the trial evidence was limited, but it at least passed the bar of a controlled study, which most dissociation medications have not.

This creates a somewhat frustrating situation for patients. Your doctor might prescribe an SSRI, it might significantly improve your mood and anxiety, and your dissociation might remain largely unchanged. That does not mean the medication was a waste. Reducing the emotional load around the dissociation can create space for psychotherapy to work, and many clinicians view the SSRI as a foundation rather than a cure for the dissociative piece. The important thing is not to assume that because the SSRI didn’t resolve the dissociation, nothing else will.

Lamotrigine Works Better as a Partner Than Solo

Lamotrigine, an antiepileptic drug that modulates glutamate signaling, has one of the more interesting stories in dissociation pharmacology. The theory behind it involves glutamate, a brain chemical involved in perception and consciousness. Some researchers have suggested that dissociation may involve an imbalance in glutamate receptor activity, and lamotrigine, which dampens excessive glutamate release, could theoretically correct that.

The clinical results are split in a revealing way. When lamotrigine was tested alone against placebo in a small controlled trial of nine patients with depersonalization disorder, it was not better than placebo. None of the patients were classified as responders to lamotrigine on its own.⁶ Taken at face value, that looks like a dead end.

But when lamotrigine was studied as an add-on to antidepressants in a larger group of 32 patients, the results were substantially more encouraging. Over half of the patients experienced at least a 30% reduction on a standard depersonalization scale.⁷ The same pattern showed up in expert commentary: open-label trials have suggested that lamotrigine combined with SSRIs can be beneficial for a “substantial number” of patients.⁵

The takeaway is that lamotrigine appears to need an SSRI working alongside it to show benefit for dissociation. The drug on its own does not seem to do much, but the combination may amplify effects in a way neither drug achieves alone. Whether that reflects a genuine synergy between glutamate modulation and serotonin reuptake inhibition, or whether the SSRI is just covering comorbid depression well enough for the lamotrigine to have something to build on, is not clear. From a practical standpoint, lamotrigine is generally well tolerated, though it requires a slow dose increase to avoid a rare but serious skin rash. If you and your prescriber are considering it, expect a gradual titration over several weeks before reaching a therapeutic dose.

Clonazepam and the Benzodiazepine Question

Benzodiazepines occupy an uncomfortable place in dissociation treatment. On one hand, clonazepam, a long-acting benzodiazepine, has been noted to help some patients with depersonalization disorder, particularly those with high levels of background anxiety. The benefit appears to come from its combination with SSRIs rather than from clonazepam on its own.⁵

On the other hand, benzodiazepines carry well-documented risks that are especially concerning for people who dissociate. They can cause cognitive dulling, memory impairment, and emotional blunting, all of which may worsen the subjective experience of detachment. Dependence develops relatively quickly, and withdrawal can be severe. For people with trauma histories, which are common among those with dissociative disorders, the risk of dependence is a serious clinical consideration. Many experts view benzodiazepines as a short-term bridge at best, something to get a patient through an acute crisis of overwhelming anxiety while other treatments are being established, not as a long-term dissociation treatment.

If a clinician does prescribe a benzodiazepine for dissociation-related anxiety, clonazepam tends to be preferred over shorter-acting options like alprazolam because its longer duration produces less of the rebound anxiety that shorter-acting drugs can cause. But this is still a situation where the treatment’s risks compete seriously with its benefits, and close monitoring matters.

Modafinil for Fog and Emotional Numbness

One of the most distressing aspects of dissociation for many people is the cognitive fog: difficulty concentrating, poor working memory, a feeling of being mentally muffled. Modafinil, a wakefulness-promoting agent typically used for narcolepsy and shift-work sleep disorder, has shown up in clinical observations as potentially helpful for these symptoms. A study of modafinil in psychiatric patients found improvements in sustained attention, working memory, concentration, and mental flexibility. Among patients with treatment-resistant symptoms including emotional numbness, poor motivation, and pervasive boredom, many reported more normal levels of both positive and negative emotion and an improved ability to engage in daily activities.⁸

Modafinil has not been studied specifically for dissociative disorders, so this is extrapolation from its effects on cognitive and motivational symptoms that overlap with what dissociating patients report. It is not addressing the root mechanism of dissociation. But for someone whose primary complaint is that they feel mentally absent, like they are watching their life through fog, the cognitive sharpening that modafinil can offer might provide real functional benefit even if the underlying dissociative process remains.

The drug is generally well tolerated, with insomnia and headache as the most common side effects. It can interact with hormonal contraceptives, reducing their effectiveness, which is worth knowing. It also has mild stimulant properties, and some people with anxiety find it activating in an uncomfortable way, so starting at a low dose and monitoring how you feel matters.

MDMA-Assisted Therapy for Dissociative PTSD

The most provocative recent development comes from MDMA-assisted therapy research. A phase 3 clinical trial of MDMA-assisted therapy for severe PTSD included participants with the dissociative subtype, a form of PTSD characterized by prominent depersonalization and derealization. These patients responded as well as those without the dissociative subtype. Participants with dissociative PTSD who received MDMA-assisted therapy showed a substantial drop in their symptom scores, roughly two and a half times the improvement seen in the placebo group.⁹

This matters because the dissociative subtype of PTSD has traditionally been considered harder to treat. The emotional numbing and detachment that characterize it can make it difficult for patients to engage with trauma-focused psychotherapy, which requires accessing and processing painful emotions. MDMA appears to lower emotional defenses enough for that processing to occur without overwhelming the patient, which may explain why it worked well even in the dissociative group.

MDMA-assisted therapy is not available as a standard clinical treatment as of this writing. The FDA declined to approve it in 2024 and requested additional data. But the trial results have energized the research community, and this remains a space worth watching for anyone with trauma-related dissociation that has not responded to conventional approaches.

Non-Drug Options That Target Dissociation Directly

Brain stimulation is emerging as a potential tool for treatment-resistant depersonalization. A case series using repetitive transcranial magnetic stimulation (rTMS) targeted at the right ventrolateral prefrontal cortex found an average 44% reduction in depersonalization scores across seven patients who had not responded to medication. Two were classified as full responders and four as partial responders.¹⁰ That is a very small sample, but for a medication-resistant condition, a 44% average symptom reduction with a non-invasive procedure is noteworthy.

rTMS uses magnetic pulses delivered through a coil placed against the scalp to stimulate specific brain areas. It is already FDA-cleared for depression and obsessive-compulsive disorder, so the technology and clinical infrastructure exist. Using it for depersonalization is still experimental, but it represents a fundamentally different approach from medication: instead of flooding the brain with a chemical and hoping it reaches the right circuits, rTMS can target a specific cortical region thought to be involved in the disorder.

Psychotherapy remains the treatment with the most consistent expert support for dissociative disorders, particularly trauma-focused approaches like EMDR and phase-oriented therapy that address the traumatic roots of dissociation. Medication is typically framed as an adjunct to therapy rather than a replacement. Many clinicians working with dissociative patients describe their pharmacological strategy as stabilizing symptoms enough for the real work of therapy to proceed, managing the sleep disruption, the anxiety, the depression, and the emotional flooding so that the patient can engage with the therapeutic process that actually resolves the dissociation over time.

What to Expect When You Ask Your Doctor

If you bring up dissociation with a prescriber, the conversation will likely start with your other symptoms. Are you depressed? An SSRI might be the first step, not because it treats dissociation well, but because it addresses the depression that often fuels and coexists with it. Are you having intense anxiety or panic? Clonazepam might come up, though a careful clinician will weigh the risks. Is your primary complaint the fog and emotional deadness? Naltrexone or lamotrigine added to an existing antidepressant could be discussed.

The honest reality is that medication for dissociation involves trial and error. A clinician familiar with the literature might try naltrexone based on the opioid-antagonist data, or add lamotrigine to your SSRI if depersonalization persists, but these are educated experiments, not protocol-driven prescriptions. You should expect your prescriber to monitor you closely, adjust doses, and be willing to change course if something is not working. You should also expect them to recommend psychotherapy alongside any medication, because the evidence consistently suggests that the best outcomes come from combining the two.

One practical point that patients often overlook: some medications can actually trigger or worsen dissociation. Cannabis is a common culprit, and many people who dissociate report that it intensifies their symptoms. Certain medications with psychoactive side effects, including some antihistamines, muscle relaxants, and even higher-dose benzodiazepines, can produce a dissociative-like cognitive haze. If you notice your dissociation worsening after starting a new medication for any condition, that is worth bringing up with your doctor promptly.

Medications That Sometimes Get Tried but Lack Evidence

A few other medications show up in clinical practice for dissociation despite having little or no research support. Antipsychotics like quetiapine or olanzapine are sometimes prescribed when dissociation includes quasi-psychotic features like voices or severe derealization, but the evidence for their benefit in dissociative disorders specifically is essentially nonexistent, and they carry significant metabolic side effects. Mood stabilizers other than lamotrigine, such as valproate, appear occasionally in treatment plans but without published data supporting their use for dissociation.

Prazosin, an alpha-1 blocker used for PTSD-related nightmares, sometimes gets tried for trauma-related dissociation on the logic that it reduces autonomic hyperarousal, which can trigger dissociative episodes. There is plausible reasoning here, but no published trials testing prazosin for dissociation specifically. Similarly, beta-blockers like propranolol are sometimes used to reduce the physical anxiety symptoms that precede dissociative episodes, functioning more as preventive tools against the anxiety trigger than as treatments for dissociation itself.

The general pattern is that the further you move from the handful of agents with any trial data, the more you are relying on clinical intuition and the hope that treating adjacent symptoms will indirectly reduce dissociation. That is not necessarily wrong, but you should know when a prescription is backed by evidence and when it is a reasonable guess.